201 603

Cited 5 times in

5-Fluorouracil, mitomycin-c, and polysaccharide-k versus uracil-ftorafur and polysaccharide-K as adjuvant chemoimmunotherapy for patients with locally advanced gastric cancer with curative resection.

Authors
Ahn, MS; Kang, SY; Lee, HW; Jeong, SH; Park, JS; Lee, KJ; Cho, YK; Han, SU; Lee, SY; Lim, HY; Choi, JH
Citation
Onkologie, 36(7-8):421-426, 2013
Journal Title
Onkologie
ISSN
0378-584X1423-0240
Abstract
BACKGROUND: Despite the small but significant survival benefit of adjuvant chemotherapy in locally advanced gastric cancer (LAGC), the optimal regimen remains to be determined. We conducted a randomized trial comparing oral (PO) chemoimmunotherapy (CITX) with intravenous (IV) CITX in LAGC patients (stages IB-IIIB) with curative resection (≥ D2 dissection).



METHODS: The patients were randomized to the IV (5-fluorouracil 500 mg/m(2) weekly for 24 weeks, mitomycin-C 8 mg/m(2) every 6 weeks × 4) or the PO (uracil-ftorafur (UFT) 400-600 mg/day for 12 months) group. Patients in both groups received PO polysaccharide-K (3 g/day for 4 months). The planned number of patients was 368 for proving the non-inferiority of PO CITX compared to IV CITX for overall survival.



RESULTS: The trial was closed prematurely after enrolling 82 patients (44 in the IV group, 38 in the PO group). With a median follow-up of 82 months, there were no significant differences in the 5-year disease-free survival (73% vs. 55%, p = 0.358) and overall survival (77% vs. 66%, p = 0.159) between the 2 groups. The IV group demonstrated a higher incidence of grade 2 or 3 neutropenia, thrombocytopenia, and vomiting.



CONCLUSIONS: PO CITX with UFT appeared to be at least non-inferior to 5-fluorouracil and mitomycin-C CITX, with lower toxicity in the adjuvant treatment for LAGC.
MeSH terms
AdultAgedAntineoplastic Combined Chemotherapy Protocols/*administration & dosageChemotherapy, Adjuvant/mortalityDisease-Free SurvivalFemaleFluorouracil/administration & dosageHumansImmunotherapy/mortalityMaleMiddle AgedMitomycin/administration & dosagePrevalenceProteoglycans/*administration & dosageRepublic of Korea/epidemiologyRisk FactorsStomach Neoplasms/*drug therapy/*mortality/surgerySurvival RateTegafur/administration & dosageTreatment OutcomeUracil/administration & dosage
DOI
10.1159/000349957
PMID
23921761
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Gastroenterology
Journal Papers > School of Medicine / Graduate School of Medicine > Surgery
Journal Papers > School of Medicine / Graduate School of Medicine > Preventive Medicine & Public Health
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
AJOU Authors
안, 미선강, 석윤이, 현우정, 성현박, 준성이, 광재조, 용관한, 상욱이, 순영최, 진혁
Full Text Link
Files in This Item:
23921761.pdfDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse